RGD Reference Report - Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer. - Rat Genome Database

Send us a Message



Submit Data |  Help |  Video Tutorials |  News |  Publications |  Download |  REST API |  Citing RGD |  Contact   

Aberrant expression and potency as a cancer immunotherapy target of alpha-methylacyl-coenzyme A racemase in prostate cancer.

Authors: Honma, I  Torigoe, T  Hirohashi, Y  Kitamura, H  Sato, E  Masumori, N  Tamura, Y  Tsukamoto, T  Sato, N 
Citation: Honma I, etal., J Transl Med. 2009 Dec 9;7:103.
RGD ID: 2315628
Pubmed: PMID:20003233   (View Abstract at PubMed)
PMCID: PMC2797764   (View Article at PubMed Central)
DOI: DOI:10.1186/1479-5876-7-103   (Journal Full-text)

Alpha-methylacyl-CoA racemase (AMACR) is an enzyme playing an important role in the beta-oxidation of branched-chain fatty acids and fatty acid derivatives. High expression levels of AMACR have been described in various cancers, including prostate cancer, colorectal cancer and kidney cancer. Because of its cancer-specific and frequent expression, AMACR could be an attractive target for cytotoxic T-lymphocyte (CTL)-based immunotherapy for cancer. In the present study, we examined the induction of AMACR-specific CTLs from prostate cancer patients' peripheral blood mononuclear cells (PBMCs) and determined HLA-A24-restricted CTL epitopes.RT-PCR and immunohistochemical analysis revealed that AMACR was strongly expressed in prostate cancer cell lines and tissues as compared with benign or normal prostate tissues. Four AMACR-derived peptides carrying the HLA-A24-binding motif were synthesized from the amino acid sequence of this protein and analyzed to determine their binding affinities to HLA-A24. By stimulating patient's PBMCs with the peptides, specific CTLs were successfully induced in 6 of 11 patients. The peptide-specific CTLs exerted significant cytotoxic activity against AMACR-expressing prostate cancer cells in the context of HLA-A24. Our study demonstrates that AMACR could become a target antigen for prostate cancer immunotherapy, and that the AMACR-derived peptides might be good peptide vaccine candidates for HLA-A24-positive AMACR-expressing cancer patients.



RGD Manual Disease Annotations    Click to see Annotation Detail View

  
Object SymbolSpeciesTermQualifierEvidenceWithNotesSourceOriginal Reference(s)
AMACRHumanProstatic Neoplasms  IEP mRNA and protein:increased expression:prostate glandRGD 
AmacrRatProstatic Neoplasms  ISOAMACR (Homo sapiens)mRNA and protein:increased expression:prostate glandRGD 
AmacrMouseProstatic Neoplasms  ISOAMACR (Homo sapiens)mRNA and protein:increased expression:prostate glandRGD 

Objects Annotated

Genes (Rattus norvegicus)
Amacr  (alpha-methylacyl-CoA racemase)

Genes (Mus musculus)
Amacr  (alpha-methylacyl-CoA racemase)

Genes (Homo sapiens)
AMACR  (alpha-methylacyl-CoA racemase)


Additional Information